

the **ADBL** report

Issue #109, July 2019

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross
The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC, (Chair)
Fiona Clement, PhD, (Vice-Chair)
Caitlin A. Clarke, BScPhm, PharmD
Margaret Gray, BSP, FCSHP
Mike Kolber, BSc, MD, CCFP, MSc
Naeem Ladhani, BScPharm
Tony Nickonchuk, BScPharm
Glen J. Pearson, BScPhm, PharmD, FCSHP, FCCS
Jeremy Slobodan, BSP
Donna Woloschuk, BSP, PharmD, M.Ed. FCSHP

ALBERTA HEALTH LIAISON:

Chad Mitchell, BSc Pharm, MSc

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)
Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Connie Lussier, BSP, MA

In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
 - ❖ *Products Originally Reviewed via the CDR*
 - ❖ *Interchangeable Drug Products Added*
 - ❖ *Line Extension Drug Products Reviewed for the ADBL*
- *Special Authorization Criteria Changes*

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on May 13, 2019. The Committee reviewed Manufacturer submissions for twelve (12) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of four (4) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, three (3) Drug Products underwent Expedited Review for listing on the ADBL effective July 1, 2019.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.html>

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Product was reviewed by CDR and the Expert Committee and added to the ADBL effective July 1, 2019:

- **PROBUPHINE* 80 mg subdermal implant** (buprenorphine hydrochloride) (KTI) via Special Authorization (SA)

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of a New IC Grouping, effective July 1, 2019:

- **MAR-FEBUXOSTAT* 80 mg tablet** (febuxostat) (MAR) via Special Authorization

Highlights of Line Extension Drug Products Reviewed for the ADBL

Addition of the following Drug Products to the *ADBL* effective July 1, 2019:

- **AA-CLOZAPINE 50 mg & 200 mg tablets** (clozapine) (AAP)

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Product has been revised effective June 17, 2019:

- **SPINRAZA* 2.4 mg/mL injection** (nusinersen sodium) (BIO)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).*